Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Protein Expr Purif ; 219: 106477, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38527576

RESUMO

Semaglutide is currently the most promising antidiabetic drug, especially for the treatment of type 2 diabetes mellitus, due to its excellent efficacy in glycemic control and weight loss. However, the production of semaglutide remains high cost, and high yield, low cost, and high purity still remains a challenge. Herein, we reported a convenient and high-yield strategy for the preparation of semaglutide through fragmented condensation coupling, involving solid-phase peptide synthesis of tetrapeptide and on-column refolding and on-column enzyme cleavage based inclusion body expression of Lys26Arg34GLP-1 (11-37) with fused protein tags in an X-Y-D4K-G pattern. The optimized N-terminal protein tag significantly boosts inclusion body expression level, while on-column refolding and on-column enzyme cleavage avoid precipitation, enhancing efficiency and yield together with one-step purification. The successful preparation of semaglutide is expected to achieve large-scale industrial production with low cost, high yield and high purity.


Assuntos
Peptídeos Semelhantes ao Glucagon , Corpos de Inclusão , Técnicas de Síntese em Fase Sólida , Peptídeos Semelhantes ao Glucagon/química , Técnicas de Síntese em Fase Sólida/métodos , Corpos de Inclusão/química , Escherichia coli/genética , Escherichia coli/metabolismo , Hipoglicemiantes/química , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA